Loading…
Symbiotec Pharmalab (SYMBIOTEC)₹1,555−2.70%Pharmaceuticals
In the Jun 2026 quarter (consolidated), Symbiotec Pharmalab reported sales of ₹218 Cr, up 7.5% from Jun 2025, and net profit of ₹13.95 Cr, down 53.3% year on year. For the year to Mar 2026, sales were ₹867 Cr and net profit ₹110 Cr.
Company filings, consolidated accounts; latest reported quarter Jun 2026
| Jun 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|
| Sales | 202 | 244 | 218 |
| Expenses | 145 | 182 | 172 |
| Operating Profit | 58.09 | 62.11 | 45.13 |
| OPM % | 29.1% | 25.1% | 21.1% |
| Other Income | 2.99 | 0.00 | 0.00 |
| Interest | 5.01 | 7.01 | 6.01 |
| Depreciation | 10.97 | 19.94 | 21.94 |
| Profit before tax | 45.18 | 35.13 | 18.05 |
| Tax % | 33.1% | 22.0% | 20.0% |
| Net Profit | 29.89 | 27.88 | 13.95 |
| EPS (Rs) | 47.15 | 4.40 | 2.25 |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Sales | 631 | 681 | 566 | 714 | 750 | 867 |
| Expenses | 437 | 548 | 495 | 542 | 547 | 628 |
| Operating Profit | 196 | 131 | 70.15 | 172 | 203 | 239 |
| OPM % | 31.1% | 19.1% | 12.1% | 24.1% | 27.1% | 27.1% |
| Other Income | 6.99 | 2.99 | 5.99 | 6.99 | 3.99 | −5.99 |
| Interest | 7.01 | 3.01 | 8.01 | 8.02 | 17.01 | 26.02 |
| Depreciation | 21.95 | 25.91 | 28.92 | 38.90 | 42.87 | 52.85 |
| Profit before tax | 174 | 105 | 39.11 | 133 | 148 | 154 |
| Tax % | 28.0% | 27.0% | 38.0% | 23.0% | 34.0% | 28.0% |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | −5.01 |
| Net Profit | 122 | 77.76 | 22.93 | 99.69 | 96.60 | 110 |
| EPS (Rs) | 113.07 | 71.04 | 21.53 | 91.69 | 152.36 | 17.56 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Equity Capital | 11.03 | 11.02 | 11.01 | 11.01 | 11.03 | 13.03 |
| Reserves | 510 | 587 | 610 | 703 | 803 | 1,135 |
| Borrowings | 47.06 | 64.98 | 218 | 247 | 544 | 391 |
| Other Liabilities | 199 | 151 | 150 | 324 | 219 | 239 |
| Total Liabilities | 767 | 813 | 988 | 1,287 | 1,578 | 1,778 |
| Fixed Assets | 261 | 280 | 299 | 448 | 438 | 1,120 |
| CWIP | 27.99 | 39.98 | 182 | 208 | 568 | 64.01 |
| Investments | 4.99 | 4.99 | 4.99 | 3.99 | 0.99 | 3.99 |
| Other Assets | 473 | 488 | 502 | 626 | 570 | 590 |
| Inventories | 227 | 247 | 245 | 337 | 262 | 238 |
| Trade receivables | 118 | 144 | 112 | 126 | 177 | 199 |
| Cash & equivalents | 48.86 | 10.96 | 5.99 | 7.98 | 25.93 | 9.97 |
| Total Assets | 767 | 813 | 988 | 1,287 | 1,578 | 1,778 |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Cash from operating activity | 174 | 18.04 | 69.17 | 188 | 47.08 | 175 |
| Cash from investing activity | −96.32 | −32.11 | −221 | −207 | −308 | −227 |
| Cash from financing activity | −78.79 | 14.95 | 146 | 21.94 | 277 | 35.93 |
| Net cash flow | −1.01 | 1.01 | −5.01 | 3.01 | 19.06 | −16.04 |
| Capex | 88.06 | 72.03 | 224 | 210 | 308 | 226 |
| Free cash flow | 86.73 | −54.81 | −155 | −21.93 | −260 | −49.86 |
| CFO / OP % | 112.0% | 36.1% | 124.1% | 129.0% | 40.1% | 99.0% |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Debtor days | 68 | 77 | 72 | 64 | 85 | 83 |
| Inventory days | 309 | 253 | 306 | 383 | 322 | 275 |
| Days payable | 154 | 90 | 109 | 258 | 108 | 159 |
| Cash conversion cycle | 222 | 239 | 268 | 188 | 299 | 198 |
| Working capital days | 85 | 120 | 106 | 75 | −4 | −23 |
| ROCE % | — | 18.0% | 6.0% | 16.0% | 14.0% | 13.0% |
For the Jun 2026 quarter, Symbiotec Pharmalab reported sales of ₹218 Cr, up 7.5% year on year and net profit of ₹13.95 Cr, down 53.3% year on year. The operating margin was 21.1%.
Symbiotec Pharmalab's sales for the year to Mar 2026 were ₹867 Cr.
Net profit for the year to Mar 2026 was ₹110 Cr. Earnings per share over the same trailing period were ₹17.56.
Symbiotec Pharmalab reported borrowings of ₹391 Cr at Mar 2026, against cash and equivalents of ₹9.97 Cr.
Cash from operations was ₹175 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹49.86 Cr.